Stock Track | Adaptive Biotechnologies Soars Over 12% Pre-Market on Analyst Upgrade

Stock Track11-08

Shares of Adaptive Biotechnologies Corp (NASDAQ: ADPT) surged more than 12% in pre-market trading on Thursday, following a positive analyst report from TD Cowen. The biotechnology company, which specializes in immune medicine, received a reiterated "Buy" rating from analyst Daniel Brennan.

In his report, Brennan highlighted Adaptive Biotechnologies' potential for growth and innovation in the field of immune-driven medicine. The analyst's optimism likely contributed to the significant pre-market rally in the company's stock price.

While the specific details of Brennan's report were not disclosed, his reiteration of a "Buy" rating suggests confidence in the company's prospects and future performance. Analyst upgrades and positive coverage can often drive short-term stock movements, as investors react to the revised expectations and valuations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160735558?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160735558","market":"hk","top_or_hot":-1,"title":"Stock Track | Adaptive Biotechnologies Soars Over 12% Pre-Market on Analyst Upgrade","media":"Stock Track","content":"<p>Shares of Adaptive Biotechnologies Corp (NASDAQ: ADPT) surged more than 12% in pre-market trading on Thursday, following a positive analyst report from TD Cowen. The biotechnology company, which specializes in immune medicine, received a reiterated \"Buy\" rating from analyst Daniel Brennan.</p>\n\n<p>In his report, Brennan highlighted Adaptive Biotechnologies' potential for growth and innovation in the field of immune-driven medicine. The analyst's optimism likely contributed to the significant pre-market rally in the company's stock price.</p>\n\n<p>While the specific details of Brennan's report were not disclosed, his reiteration of a \"Buy\" rating suggests confidence in the company's prospects and future performance. Analyst upgrades and positive coverage can often drive short-term stock movements, as investors react to the revised expectations and valuations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Adaptive Biotechnologies Soars Over 12% Pre-Market on Analyst Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Adaptive Biotechnologies Soars Over 12% Pre-Market on Analyst Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 21:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Adaptive Biotechnologies Corp (NASDAQ: ADPT) surged more than 12% in pre-market trading on Thursday, following a positive analyst report from TD Cowen. The biotechnology company, which ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"","article_id":"1160735558","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160735558","pubTimestamp":1731071044,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Adaptive Biotechnologies Corp  surged more than 12% in pre-market trading on Thursday, following a positive analyst report from TD Cowen. The biotechnology company, which specializes in immune medicine, received a reiterated \"Buy\" rating from analyst Daniel Brennan.In his report, Brennan highlighted Adaptive Biotechnologies' potential for growth and innovation in the field of immune-driven medicine. The analyst's optimism likely contributed to the significant pre-market rally in the co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"分析师升级后，Adaptive Biotechnologies股价盘前飙升逾12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"Shares of Adaptive Biotechnologies Corp (NASDAQ: ADPT) surged more than 12% in pre-market trading on Thursday, following a positive analyst report from TD Cowen. The biotechnology company, which specializes in immune medicine, received a reiterated \"Buy\" rating from analyst Daniel Brennan.\nIn his report, Brennan highlighted Adaptive Biotechnologies' potential for growth and innovation in the field of immune-driven medicine. The analyst's optimism likely contributed to the significant pre-market rally in the company's stock price.\nWhile the specific details of Brennan's report were not disclosed, his reiteration of a \"Buy\" rating suggests confidence in the company's prospects and future performance. Analyst upgrades and positive coverage can often drive short-term stock movements, as investors react to the revised expectations and valuations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160735558"}